ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) has been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 1 year consensus price target of $4.50 for the company, according to Zacks. Zacks has also assigned ContraVir Pharmaceuticals an industry rank of 101 out of 265 based on the ratings given to its competitors.

Separately, Maxim Group reiterated a “buy” rating and set a $4.00 price objective on shares of ContraVir Pharmaceuticals in a report on Thursday, August 24th.

An institutional investor recently raised its position in ContraVir Pharmaceuticals stock. Vanguard Group Inc. raised its position in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 17.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,414,475 shares of the biopharmaceutical company’s stock after acquiring an additional 366,192 shares during the quarter. Vanguard Group Inc. owned 3.79% of ContraVir Pharmaceuticals worth $1,400,000 at the end of the most recent quarter. 6.65% of the stock is owned by hedge funds and other institutional investors.

Shares of ContraVir Pharmaceuticals (CTRV) traded down $0.01 during mid-day trading on Thursday, hitting $0.34. 900,100 shares of the stock traded hands, compared to its average volume of 940,285. ContraVir Pharmaceuticals has a 1-year low of $0.32 and a 1-year high of $2.07.

WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at

ContraVir Pharmaceuticals Company Profile

Get a free copy of the Zacks research report on ContraVir Pharmaceuticals (CTRV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with's FREE daily email newsletter.